Currently several AKT inhibitors are under evaluation in clinical trials, while mTOR inhibitors such as temsirolimus and analogs have been approved by US Food and Drug Administration for the treatment of various cancers (Zhu et al., 2014), which light hope for novel ones for AML treatment. This evidence concerns the gene AKT1 and cancer.